Plasmodium vivax : who cares?

Abstract More attention is being focused on malaria today than any time since the world's last efforts to achieve eradication over 40 years ago. The global community is now discussing strategies aimed at dramatically reducing malarial disease burden and the eventual eradication of all types of...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Barnwell John W, Galinski Mary R
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2008
Subjects:
Online Access:https://doi.org/10.1186/1475-2875-7-S1-S9
https://doaj.org/article/87bf45f98bf349e3939a8005265683e2
id ftdoajarticles:oai:doaj.org/article:87bf45f98bf349e3939a8005265683e2
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:87bf45f98bf349e3939a8005265683e2 2023-05-15T15:14:44+02:00 Plasmodium vivax : who cares? Barnwell John W Galinski Mary R 2008-12-01T00:00:00Z https://doi.org/10.1186/1475-2875-7-S1-S9 https://doaj.org/article/87bf45f98bf349e3939a8005265683e2 EN eng BMC http://www.malariajournal.com/content/7/S1/S9 https://doaj.org/toc/1475-2875 doi:10.1186/1475-2875-7-S1-S9 1475-2875 https://doaj.org/article/87bf45f98bf349e3939a8005265683e2 Malaria Journal, Vol 7, Iss Suppl 1, p S9 (2008) Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2008 ftdoajarticles https://doi.org/10.1186/1475-2875-7-S1-S9 2022-12-31T00:48:11Z Abstract More attention is being focused on malaria today than any time since the world's last efforts to achieve eradication over 40 years ago. The global community is now discussing strategies aimed at dramatically reducing malarial disease burden and the eventual eradication of all types of malaria, everywhere. As a consequence, Plasmodium vivax , which has long been neglected and mistakenly considered inconsequential, is now entering into the strategic debates taking place on malaria epidemiology and control, drug resistance, pathogenesis and vaccines. Thus, contrary to the past, the malaria research community is becoming more aware and concerned about the widespread spectrum of illness and death caused by up to a couple of hundred million cases of vivax malaria each year. This review brings these issues to light and provides an overview of P. vivax vaccine development, then and now. Progress had been slow, given inherent research challenges and minimal support in the past, but prospects are looking better for making headway in the next few years. P. vivax , known to invade the youngest red blood cells, the reticulocytes, presents a strong challenge towards developing a reliable long-term culture system to facilitate needed research. The P. vivax genome was published recently, and vivax researchers now need to coordinate efforts to discover new vaccine candidates, establish new vaccine approaches, capitalize on non-human primate models for testing, and investigate the unique biological features of P. vivax , including the elusive P. vivax hypnozoites. Comparative studies on both P. falciparum and P. vivax in many areas of research will be essential to eradicate malaria. And to this end, the education and training of future generations of dedicated "malariologists" to advance our knowledge, understanding and the development of new interventions against each of the malaria species infecting humans also will be essential. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Malaria Journal 7 S1
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
spellingShingle Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Barnwell John W
Galinski Mary R
Plasmodium vivax : who cares?
topic_facet Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
description Abstract More attention is being focused on malaria today than any time since the world's last efforts to achieve eradication over 40 years ago. The global community is now discussing strategies aimed at dramatically reducing malarial disease burden and the eventual eradication of all types of malaria, everywhere. As a consequence, Plasmodium vivax , which has long been neglected and mistakenly considered inconsequential, is now entering into the strategic debates taking place on malaria epidemiology and control, drug resistance, pathogenesis and vaccines. Thus, contrary to the past, the malaria research community is becoming more aware and concerned about the widespread spectrum of illness and death caused by up to a couple of hundred million cases of vivax malaria each year. This review brings these issues to light and provides an overview of P. vivax vaccine development, then and now. Progress had been slow, given inherent research challenges and minimal support in the past, but prospects are looking better for making headway in the next few years. P. vivax , known to invade the youngest red blood cells, the reticulocytes, presents a strong challenge towards developing a reliable long-term culture system to facilitate needed research. The P. vivax genome was published recently, and vivax researchers now need to coordinate efforts to discover new vaccine candidates, establish new vaccine approaches, capitalize on non-human primate models for testing, and investigate the unique biological features of P. vivax , including the elusive P. vivax hypnozoites. Comparative studies on both P. falciparum and P. vivax in many areas of research will be essential to eradicate malaria. And to this end, the education and training of future generations of dedicated "malariologists" to advance our knowledge, understanding and the development of new interventions against each of the malaria species infecting humans also will be essential.
format Article in Journal/Newspaper
author Barnwell John W
Galinski Mary R
author_facet Barnwell John W
Galinski Mary R
author_sort Barnwell John W
title Plasmodium vivax : who cares?
title_short Plasmodium vivax : who cares?
title_full Plasmodium vivax : who cares?
title_fullStr Plasmodium vivax : who cares?
title_full_unstemmed Plasmodium vivax : who cares?
title_sort plasmodium vivax : who cares?
publisher BMC
publishDate 2008
url https://doi.org/10.1186/1475-2875-7-S1-S9
https://doaj.org/article/87bf45f98bf349e3939a8005265683e2
geographic Arctic
geographic_facet Arctic
genre Arctic
genre_facet Arctic
op_source Malaria Journal, Vol 7, Iss Suppl 1, p S9 (2008)
op_relation http://www.malariajournal.com/content/7/S1/S9
https://doaj.org/toc/1475-2875
doi:10.1186/1475-2875-7-S1-S9
1475-2875
https://doaj.org/article/87bf45f98bf349e3939a8005265683e2
op_doi https://doi.org/10.1186/1475-2875-7-S1-S9
container_title Malaria Journal
container_volume 7
container_issue S1
_version_ 1766345163947376640